United States — Food and Drug Administration & AnBogen Therapeutics
6 shared events · Importance 3 · Last updated Sep 01, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA provided written pre-IND responses raising no objections to Protagenic's Phase 1 program design and supporting packages, facilitating the company's path to IND submission. This action reflects the FDA's regulatory role in evaluating investigational drugs.
AnBogen Therapeutics: AnBogen Therapeutics is the developer of PT00114 and the recipient of FDA's pre-IND feedback. This positive regulatory milestone supports its clinical development plans and may enhance its market position, though the company still faces substantial financial and clinical risks.
Aug 20, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA approved Mimrylo and Besremi, expanding treatment options for rare blood cancers. Its decisions shape the regulatory landscape for these therapies.
AnBogen Therapeutics: Protagonist receives $275 million in payments and up to $875 million more plus royalties, boosting its financial independence and funding its pipeline. Its stock has nearly tripled over the past year.
Aug 28, 2026 · 6 articles
Business
United States — Food and Drug Administration: Granted Orphan Drug and Rare Pediatric Disease Designations for SYN-001; provided preliminary alignment on endpoints.
AnBogen Therapeutics: Founding investor and development partner; CEO Ivar Hakonarson becomes Chairman of Synaptiq.
Jul 23, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide for the treatment of polycythemia vera.
AnBogen Therapeutics: AnBogen Therapeutics granted inducement awards to three new employees, consisting of stock options and restricted stock units, as a material inducement for their employment. This action aims to attract and retain talent, which is generally positive for the company's long-term prospects.
Jun 16, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is currently reviewing the New Drug Application for rusfertide.
AnBogen Therapeutics: AnBogen Therapeutics will participate in two investment bank conferences, providing an opportunity to present its pipeline and potentially attract investor interest.
May 28, 2026 · 6 articles
Business
United States — Food and Drug Administration: The FDA is reviewing the NDA for rusfertide. This event does not affect the FDA.
AnBogen Therapeutics: Protagonist granted inducement awards to new employees, reflecting ongoing talent acquisition. The company's pipeline includes ICOTYDE and rusfertide, with regulatory milestones ahead.
Aug 04, 2026 · 9 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and AnBogen Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard